Introduction
Breast cancer remains one of the most common cancers affecting women worldwide, prompting ongoing efforts to optimize screening methods to detect tumors early when treatment is most effective. Traditionally, many guidelines have recommended annual mammograms starting at age 40 or 50, regardless of individual risk. However, this “one-size-fits-all” approach may lead to unnecessary procedures for low-risk women and missed opportunities for enhanced surveillance in those at higher risk. To address this, the WISDOM (Women Informed to Screen Depending On Measures of risk) randomized clinical trial explored whether a risk-based screening strategy, incorporating genetic testing and clinical risk models, could safely and efficiently replace routine annual mammography.
